Department of Urology, Medical University of Graz, Graz, Austria.
Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
Urol Int. 2021;105(9-10):777-785. doi: 10.1159/000516941. Epub 2021 Jun 28.
The aim of this study was to evaluate long-term safety and efficacy of the suprapubic arc (SPARC) procedure for the surgical treatment of stress urinary incontinence (SUI).
139 female patients treated by SPARC were included in this retrospective analysis, whereby 126 patients were available for follow-up after 1 year, 70 after 6 years, and 41 after 9 years. The cough test, pad test, uroflowmetry, and post-void residual volume measurements were performed. Severity of bother (visual analogous scale [VAS] 0-10), continence, and the satisfaction rate were assessed. Objective cure was defined as a negative cough test and pad weight ≤1 g, subjective cure as no urine loss during daily activities and no usage of pads. The VAS, pad weight, number of pads per day, and maximal flow rate were compared preoperatively and postoperatively.
Objective cure rates at 1, 6, and 9 years were 78.6, 71.4, and 70.7% and subjective cure rates were 72.2, 55.7, and 65.8%, respectively. The VAS, pad weight, number of pads, and maximal flow rate decreased significantly. Study limitations include a relatively small sample size and the retrospective fashion of the analysis.
In the long-term context, SPARC showed to represent an efficient and safe procedure for treatment of female SUI.
本研究旨在评估耻骨上弓（SPARC）手术治疗压力性尿失禁（SUI）的长期安全性和疗效。
本回顾性分析纳入了 139 例接受 SPARC 治疗的女性患者，其中 126 例患者在 1 年后可随访，70 例在 6 年后，41 例在 9 年后。进行咳嗽试验、垫试验、尿流率和残余尿量测量。评估严重程度（视觉模拟量表[VAS]0-10）、尿失禁情况和满意度。客观治愈定义为咳嗽试验阴性和垫重≤1g，主观治愈定义为日常活动时无尿漏且不使用垫。比较术前和术后 VAS、垫重、每天使用垫的数量和最大流量。
1 年、6 年和 9 年的客观治愈率分别为 78.6%、71.4%和 70.7%，主观治愈率分别为 72.2%、55.7%和 65.8%。VAS、垫重、垫的数量和最大流量均显著降低。研究局限性包括样本量相对较小和分析的回顾性方式。
在长期随访中，SPARC 对女性 SUI 的治疗显示出有效且安全的疗效。
